Date | Title & Description | Contributors |
---|---|---|
2024-05-15 |
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC Host: Jhanelle E. Gray, MD Guest: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinic... |
|
2024-05-15 |
Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC Host: Jhanelle E. Gray, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicitie... |
|
2024-05-15 | Host: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities... | |
2024-05-15 |
Consolidation Immunotherapy After Concurrent CRT: What Do Real-World Data Show? Host: Jhanelle E. Gray, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicitie... |
|
2024-05-15 |
Immunotherapy Approaches in Unresectable Stage III NSCLC: What’s on the Horizon? Host: Jhanelle E. Gray, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicitie... |
|
2024-05-15 |
Optimizing Consolidative Immunotherapy in Unresectable Stage III NSCLC: Case Discussion Host: Joshua E. Reuss, MD Guest: Jhanelle E. Gray, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinic... |
|
2024-05-15 |
Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy? Host: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities... |
|
2024-05-15 |
Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers Host: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities... |
|
2024-05-15 |
Differentiating and Managing Pneumonitis in Unresectable Stage III NSCLC: Case Discussion Host: Jhanelle E. Gray, MD Guest: Joshua E. Reuss, MD In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinic... |
|
2024-05-14 | Host: Mazyar Shadman, MD, MPH Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all ... |